Have you secured your place at the Protein Degradation & Targeting Undruggables Congress Europe yet? Join companies in attendance, such as: Amphista Therapeutics Limited, AstraZeneca, Bayer, Biognosys, Boehringer Ingelheim, C4 Therapeutics, Inc., Captor Therapeutics SA, Collaborative Drug Discovery - CDD VAULT, Celeris Therapeutics, Cellestia Biotech, Concept Life Sciences, Cullgen Inc., Dunad Therapeutics, Enamine PL, ETH Zürich, Fida Biosystems, FIMECS, Inc., Firefly Biologics, Flagship Pioneering, Genentech and GSK The final EARLY BIRD discount ends this Friday! (August 25) Register now and save up to €300: https://lnkd.in/efyfd4ZA #molecularbiology #protac #oncology #proteindegradation
About us
Dedicated to supporting the development of novel pharmaceutical modalities – RNA therapeutics, protein degraders, transcription inhibitors – these conferences provide exclusive insight to pioneering drug development programs, the most influential and important stakeholders, and invaluable horizon scanning for researchers. Focused agendas will provide an in-depth review of industry drug pipelines, pinpoint structural biology and computational advancements, and inform R&D teams on re-engineering strategies for experimental nucleic-acid, biologic and small-molecule compounds. In the changing landscape of undruggability, join this biopharma-led series to remain at the forefront of the next generation of novel therapeutic entities.
- Industry
- Research Services
- Company size
- 11-50 employees
- Headquarters
- Basel
- Type
- Privately Held
- Founded
- 2019
- Specialties
- undruggables, protein degradation, Targeting RNA, drug discovery, protein misfolding, and neurodegenerative disease
Updates
-
Thank you to our sponsors for supporting the 5th Edition of Protein Degradation & Targeting Undruggables Congress Pelago Bioscience AB Promega Corporation Biognosys Tcg Life Science Collaborative Drug Discovery - CDD VAULT Jubilant Biosys Limited Fida Biosystems Proteome Sciences plc Sygnature Discovery Concept Life Sciences o2h discovery https://hubs.ly/Q022vS330
-
-
Next up is a panel on Cross Functional Collaboration on Translational Safety of Targeted Protein Degraders with Novartis AstraZeneca and Bayer See you soon!
-
-
Join Chris Nasveschuk from C4 Therapeutics, Inc. as he delves into binary binding affinity and its impact on degradation activity at #PDTUEU https://hubs.ly/Q022vGX20
-
-
Welcome to the Congress Center Basel! We look forward to meeting everyone at the most established European event for undruggable drug discovery! #PDTUEU https://hubs.ly/Q022vPk30
-